Aerska Therapeutics vs Saama Analytics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Raised $39M (Feb 2026, doubled from $21M Series A). Brain-shuttle + RNAi delivery for genetic Alzheimer's and Parkinson's. Non-viral CNS delivery crossing blood-brain barrier.
About
Aerska Therapeutics is developing a brain-shuttle RNAi (RNA interference) platform for CNS gene silencing — specifically targeting the genetic forms of Alzheimer's disease and Parkinson's disease caused by dominant mutations that can be silenced by RNA therapeutics. The company raised $39 million in February 2026, doubling its prior $21 million Series A round, led by ex-AstraZeneca neuroscience executives who validated both the science and the commercial opportunity.
Saama Analytics is the #1 AI clinical analytics platform for life sciences; received up to $430M Carlyle-led investment in May 2025; serves 50+ biotech companies across 1,500+ studies including top-20 pharma.
About
Saama Analytics is the leading AI-driven clinical analytics and data management platform for the life sciences industry, positioning itself as the "#1 in AI Clinical Analytics" based on customer adoption across major pharmaceutical and biotechnology companies. Founded and headquartered in the United States, Saama's Life Science Analytics Cloud (LSAC) platform accelerates clinical trial execution by automating data processing, quality checking, safety signal detection, and regulatory submission preparation — tasks that traditionally require significant manual effort from biostatisticians, data managers, and clinical programmers.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.